{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:11:02Z","timestamp":1793034662133,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.berh.2020.101657","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T21:53:57Z","timestamp":1608674037000},"page":"101657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes"],"prefix":"10.1016","volume":"35","author":[{"given":"Rebecca","family":"Grainger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2020.101657_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12931-020-01479-w","article-title":"From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses","volume":"21","author":"Zhu","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.berh.2020.101657_bib2","article-title":"Antirheumatic disease therapies for the treatment of COVID-19: a systematic review and meta-analysis","author":"Putman","year":"2020","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2020.101657_bib3","first-page":"2020","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","author":"Akiyama","year":"2020","journal-title":"Annals of the Rheumatic Diseases annrheumdis\u2013"},{"key":"10.1016\/j.berh.2020.101657_bib4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.semarthrit.2020.05.001","article-title":"Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs","volume":"50","author":"Michelena","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2020.101657_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30227-7","article-title":"COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study","author":"Zhong","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2020.101657_bib6","article-title":"Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD","author":"Benucci","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101657_bib7","article-title":"Susceptibility to COVID-19 in patients treated with antimalarials: a population based study in Emilia-Romagna, Northern Italy","author":"Salvarani","year":"2020","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2020.101657_bib8","article-title":"Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study","author":"Pablos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101657_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/art.41388","article-title":"Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?","author":"Favalli","year":"2020","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2020.101657_bib10","article-title":"Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration","volume":"e13475","author":"Damiani","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.berh.2020.101657_bib11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/rheumatology\/keaa191","article-title":"The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance","volume":"59","author":"Wallace","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2020.101657_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/rheumatology\/keaa483","article-title":"The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice","volume":"60","author":"Liew","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2020.101657_bib13","article-title":"Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries","volume":"2 e250\u2013e253","author":"Gianfrancesco","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2020.101657_bib14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101657_bib15","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMsa2011686","article-title":"Hospitalization and mortality among black patients and white patients with covid-19","volume":"382","author":"Price-Haywood","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2020.101657_bib16","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.05.032","article-title":"Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry","author":"Brenner","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.berh.2020.101657_bib17","first-page":"2020","article-title":"Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases","author":"Nu\u00f1ez","year":"2020","journal-title":"Annals of the Rheumatic Diseases annrheumdis\u2013"},{"key":"10.1016\/j.berh.2020.101657_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMc2009567","article-title":"Covid-19 in immune-mediated inflammatory diseases - case series from New York","volume":"383","author":"Haberman","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2020.101657_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/art.41456","article-title":"COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and DMARDs on clinical outcomes","author":"Haberman","year":"2020","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2020.101657_bib20","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/annrheumdis-2020-217888","article-title":"Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US \u2018hot spot\u2019","volume":"79","author":"D\u2019Silva","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101657_bib21","first-page":"2 e549","article-title":"COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case\u2013control study","author":"Fredi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2020.101657_bib22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.berh.2020.101657_bib23","first-page":"887","article-title":"IBD in the COVID-19 era: the value of international collaboration","volume":"5","author":"Brenner","year":"2020","journal-title":"Lancet Gastro Hep"},{"key":"10.1016\/j.berh.2020.101657_bib24","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.berh.2020.101657_bib25","doi-asserted-by":"crossref","first-page":"e9965","DOI":"10.7717\/peerj.9965","article-title":"Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs","volume":"8","author":"Kouznetsova","year":"2020","journal-title":"Peer J"},{"key":"10.1016\/j.berh.2020.101657_bib26","author":"Omar","year":"2020"},{"key":"10.1016\/j.berh.2020.101657_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.autrev.2008.05.001","article-title":"DMARDS and infections in rheumatoid arthritis","volume":"8","author":"Caporali","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2020.101657_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41584-020-0418-0","article-title":"The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic","volume":"16","author":"Robinson","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2020.101657_bib29","article-title":"SARS CoV-2 infection among patients using immunomodulatory therapies","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2020.101657_bib30","doi-asserted-by":"crossref","first-page":"E653","DOI":"10.1016\/S2665-9913(20)30309-X","article-title":"Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment","volume":"2","author":"Robinson","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2020.101657_bib31","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2020.101657_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16761","article-title":"Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19","author":"Fougerousse","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2020.101657_bib33","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS: observational study of early experience from NYU multiple sclerosis comprehensive care center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.berh.2020.101657_bib34","article-title":"Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis","author":"Mantero","year":"2020","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.berh.2020.101657_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","author":"Louapre","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.berh.2020.101657_bib36","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/BOR.0000000000000725","article-title":"Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases","volume":"32","author":"Gianfrancesco","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2020.101657_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/art.41447","article-title":"COVID-19 in rheumatic diseases: a research agenda","author":"Yazdany","year":"2020","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2020.101657_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/acr2.11148","article-title":"Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic","volume":"2","author":"Michaud","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.berh.2020.101657_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3899\/jrheum.200646","article-title":"Attitudes and behaviours of patients with rheumatic diseases during the early stages of the COVID-19 outbreak","volume":"48","author":"Ma","year":"2021","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2020.101657_bib41","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2665-9913(20)30286-1","article-title":"Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population","volume":"2","author":"Hooijberg","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2020.101657_bib42","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/art.41301","article-title":"American College of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1","volume":"72","author":"Mikuls","year":"2020","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.berh.2020.101657_bib43","first-page":"e1","article-title":"American College of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 2","volume":"72","author":"Mikuls","year":"2020","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.berh.2020.101657_bib44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2020-217877","article-title":"EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101657_bib45","doi-asserted-by":"crossref","first-page":"146","DOI":"10.18773\/austprescr.2020.058","article-title":"Management of autoimmune disease during the COVID-19 pandemic","volume":"43","author":"Robinson","year":"2020","journal-title":"Aust Prescr"},{"key":"10.1016\/j.berh.2020.101657_bib46","article-title":"Dexamethasone in hospitalized patients with covid-19 - preliminary report","author":"Horby","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2020.101657_bib47","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.berh.2020.101657_bib48","series-title":"Tocilizumab in hospitalized patients with COVID-19 pneumonia","volume":"13","author":"Rosas","year":"2020"},{"key":"10.1016\/j.berh.2020.101657_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.berh.2020.101657_bib50","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2020.101657_bib51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2020.12603","article-title":"COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19","volume":"324","author":"Carf\u00ec","year":"2020","journal-title":"J\u00a0Am Med Assoc"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220301741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220301741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:21:47Z","timestamp":1761499307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694220301741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1521694220301741"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2020.101657","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2020.101657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101657"}}